Aug. 14 at 7:15 PM
$NVDA The latest PR reinforces that clinical development isn't defined by a single number—it's built through consistent evidence over time. While NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%), the study also reported a median overall survival of 26.1 months.
The evidence continues to evolve. With five patients still receiving treatment, the clinical dataset is still growing, providing additional insight into NEO100's long-term clinical profile.
As therapies like temozolomide have shown over time, lasting clinical impact is built through accumulating evidence—not a single readout.
$NTHI $MRK $EXEL $CGON
